Mutant sodium channel for tumor therapy

Molecular Therapy

Volumn 17, Issue 5, 2009, Pages 810-819

  Tannous, Bakhos A ^a   Christensen, Adam P ^a   Pike, Lisa ^a   Wurdinger, Thomas ^a   Perry, Katherine F ^a   Saydam, Okay ^a   Jacobs, Andreas H ^b   García Añoveros, Jaime ^c   Weissleder, Ralph ^a   Sena Esteves, Miguel ^a   Corey, David P ^a,d   Breakefield, Xandra O ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MAX PLANCK INSTITUTE FOR NEUROLOGICAL RESEARCH   (Germany)

^c NORTHWESTERN UNIVERSITY   (United States)

^d HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; EPITHELIAL SODIUM CHANNEL; HERPESVIRUS VECTOR; MUTANT PROTEIN; PROTEIN ASIC2A; REGULATOR PROTEIN; SODIUM CHANNEL; UNCLASSIFIED DRUG;

AMPLICON; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOLUMINESCENCE; CANCER CELL CULTURE; CANCER GENE THERAPY; CELL DEATH; CELL SWELLING; CONTROLLED STUDY; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; GENE MUTATION; GENE SILENCING; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PATCH CLAMP; SKIN TUMOR; SODIUM TRANSPORT; TUMOR REGRESSION; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY;

HUMAN HERPESVIRUS 1; HUMAN HERPESVIRUS 4; MAMMALIA; MUS MUSCULUS;

EID: 67349163024     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2009.33     Document Type: Article

References (50)

1. Chiocca, EA, Broaddus, WC, Gillies, GT, Visted, T and Lamfers, ML (2004). Neurosurgical delivery of chemotherapeutics, targeted toxins, genetic and viral therapies in neuro-oncology. J Neurooncol 69 101-117.
2. Lam, YP and Breakefield, XO (2001). Potential of gene therapy for brain tumors. Hum Mol Genet 10: 777-787.
3. Yang, ZR, Wang, HF, Zhao, J, Peng, YY, Wang, J, Guinn, BA et al. (2007). Recent developments in the use of adenoviruses and immunotoxins in cancer gene therapy. Cancer Gene Ther 14: 599-615.
4. Hodi, FS and Dranoff, G (2006). Combinatorial cancer immunotherapy. Adv Immunol 90: 341-368.
5. Ochsenbein, AF (2002). Principles of tumor immunosurveillance and implications for immunotherapy. Cancer Gene Ther 9: 1043-1055.
6. Aghi, M, Hochberg, F and Breakefield, XO (2000). Prodrug activation enzymes in cancer gene therapy. J Gene Med 2: 148-164.
7. Schepelmann, S and Springer, CJ (2006). Viral vectors for gene-directed enzyme prodrug therapy. Curr Gene Ther 6: 647-670.
8. Zhang, L and Fang, B (2005). Mechanisms of resistance to TRAIL-induced apoptosis in cancer. Cancer Gene Ther 12: 228-237.
9. Dingli, D, Russell, SJ and Morris, JC (2003). In vivo imaging and tumor therapy with the sodium iodide symporter. J Cell Biochem 90: 1070-1086.
10. Ljunggren, K, Liu, X, Erlandsson, K, Ljungberg, M, Salford, L and Strand, SE (2004). Absorbed dose distribution in glioma tumors in rat brain after therapeutic intratumoral injection of 201Tl-chloride. Cancer Biother Radiopharm 19: 562-569.
11. Mamelak, AN, Rosenfeld, S, Bucholz, R, Raubitschek, A, Nabors, LB, Fiveash, JB et al. (2006). Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. J Clin Oncol 24: 3644-3650.
12. Hampl, J, Brown, A, Rainov, N and Breakefield, XO (2001). Methods for gene delivery to neural tissue. In: Chin, HR, Moldin, SO (eds). Methods in Genomic Neuroscience. CRC Press: Baton Rouge, FL, pp. 229-265.
13. Vähä-Koskela, MJ, Heikkilä, JE and Hinkkanen, AE (2007). Oncolytic viruses in cancer therapy. Cancer Lett 254: 178-216.
14. Hadaczek, P, Kohutnicka, M, Krauze, MT, Bringas, J, Pivirotto, P, Cunningham, J et al. (2006). Convection-enhanced delivery of adeno-associated virus type 2 (AAV2) into the striatum and transport of AAV2 within monkey brain. Hum Gene Ther 17: 291-302.
15. McKee, TD, Grandi, P, Mok, W, Alexandrakis, G, Insin, N, Zimmer, JP et al. (2006). Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 66: 2509-2513.
16. Shah, K and Breakefield, X (2006). HSV amplicon vectors for cancer therapy. Curr Gene Ther 6: 361-370.
17. Hampl, JA, Camp, SM, Mydlarz, WK, Hampl, M, Ichikawa, T, Chiocca, EA et al. (2003). Potentiated gene delivery to tumors using herpes simplex virus/Epstein-Barr virus/RV tribrid amplicon vectors. Hum Gene Ther 14: 611-626.
18. Wang, S and Vos, JM (1996). A hybrid herpesvirus infectious vector based on Epstein-Barr virus and herpes simplex virus type 1 for gene transfer into human cells in vitro and in vivo. J Virol 70: 8422-8430.
19. Wang, S, Fraefel, C and Breakefield, XO (2002). HSV-1 amplicon vectors. In: Philips, I (ed.). Methods in Enzymology, Gene Therapy Methods. pp. 593-603.
20. García-Añoveros, J, Derfler, B, Neville-Golden, J, Hyman, BT and Corey, DP (1997). BNaC1 and BNaC2 constitute a new family of human neuronal sodium channels related to degenerins and epithelial sodium channels. Proc Natl Acad Sci USA 94: 1459-1464.
21. Jasti, J, Furukawa, H, Gonzales, EB and Gouaux, E (2007). Structure of acid-sensing ion channel 1 at 1.9 A resolution and low pH. Nature 449: 316-323.
22. Waldmann, R, Champigny, G, Voilley, N, Lauritzen, I and Lazdunski, M (1996). The mammalian degenerin MDEG, an amiloride-sensitive cation channel activated by mutations causing neurodegeneration in Caenorhabditis elegans. J Biol Chem 27: 10433-10436.
23. García-Añoveros, J, García, JA, Liu, JD and Corey, DP (1998). The nematode degenerin UNC-105 forms ion channels that are activated by degeneration- or hypercontraction-causing mutations. Neuron 20 1231-1241.
24. Chalfie, M and Wolinsky, E (1990). The identification and suppression of inherited neurodegeneration in Caenorhabditis elegans. Nature 345: 410-416.
25. García-Añoveros, J, Ma, C and Chalfie, M (1995). Regulation of Caenorhabditis elegans degenerin proteins by a putative extracellular domain. Curr Biol 5: 441-448.
26. Bragg, DC, Camp, SM, Kaufman, CA, Wilbur, JD, Boston, H, Schuback, DE et al. (2004). Perinuclear biogenesis of mutant torsin-A inclusions in cultured cells infected with tetracycline-regulated herpes simplex virus type 1 amplicon vectors. Neuroscience 125: 651-661.
27. Freundlieb, S, Schirra-Müller, C and Bujard, H (1999). A tetracycline controlled activation/repression system with increased potential for gene transfer into mammalian cells. J Gene Med 1: 4-12.
28. Baron, U, Freundlieb, S, Gossen, M and Bujard, H (1995). Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res 23: 3605-3606.
29. Saeki, Y, Breakefield, XO and Chiocca, EA (2003). Improved HSV-1 amplicon packaging system using ICP27-deleted, oversized HSV-1 BAC DNA. Methods Mol Med 76: 51-60.
30. Badr, CE, Hewett, JW, Breakefield, XO and Tannous, BA (2007). A highly sensitive assay for monitoring the secretory pathway and ER stress. PLoS ONE 2: E571.
31. Tannous, BA, Kim, DE, Fernandez, JL, Weissleder, R and Breakefield, XO (2005). Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11: 435-443.
32. Wurdinger, T, Badr, C, Pike, L, de Kleine, R, Weissleder, R, Breakefield, XO et al. (2008). A secreted luciferase for ex vivo monitoring of in vivo processes. Nat Methods 5 171-173.
33. Aboody, KS, Brown, A, Rainov, NG, Bower, KA, Liu, S, Yang, W et al. (2000). Neural stem cells display extensive tropism for pathology in adult brain: Evidence from intracranial gliomas. Proc Natl Acad Sci USA 97: 12846-12851.
34. Shah, K, Jacobs, A, Breakefield, XO and Weissleder, R (2004). Molecular imaging of gene therapy for cancer. Gene Ther 11: 1175-1187.
35. Briat, A and Vassaux G (2006). Preclinical applications of imaging for cancer gene therapy. Expert Rev Mol Med 8: 1-19.
36. Ullrich, N, Bordey, A, Gillespie, GY and Sontheimer, H (1998). Expression of voltate-activated chloride currents in acute slices of human gliomas. Neurosci 83: 1161-1173.
37. Deshane, J, Garner, CC and Sontheimer, H (2003). Chlorotoxin inhibits glioma cell invasion via matrix metalloproteinase-2. J Biol Chem 278: 4135-4144.
38. Ernest, NJ, Weaver, AK, Van Duyn, LB and Sontheimer, HW (2005). Relative contribution of chloride channels and transporters to regulatory volume decrease in human glioma cells. Am J Physiol 288: C1451-C1460.
39. Shen, MR, Chou, CY and Ellory, JC (2000). Volume-sensitive KCI cotransport associated with human cervical carcinogenesis. Pflugers Arch 440: 751-760.
40. Riesco-Eizaguirre, G and Santisteban, P (2006). A perspective view of sodium iodide symporter research and its clinical implications. Eur J Endocrinol 155: 495-512.
41. Huang, M, Batra, RK, Kogai, T, Lin, YQ, Hershman, JM, Lichtenstein, A et al. (2001). Ectopic expression of the thyroperoxidase gene augments radioiodide uptake and retention mediated by the sodium iodide symporter in non-small cell lung cancer. Cancer Gene Ther 8: 612-618.
42. Furuya, F, Shimura, H, Miyazaki, A, Taki, K, Ohta, K, Haraguchi, K et al. (2004). Adenovirus-mediated transfer of thyroid transcription factor-1 induces radioiodide organification and retention in thyroid cancer cells. Endocrinology 145: 5397-5405.
43. Dingli, D, Kemp, BJ, O'Connor, MK, Morris, JC, Russell, SJ and Lowe, VJ (2006). Combined I-124 positron emission tomography/computed tomography imaging of NIS gene expression in animal models of stably transfected and intravenously transfected tumor. Mol Imaging Biol 8: 16-23.
44. Oliveira, R, Christov, C, Guillamo, JS, de Bouard, S, Palfi, S, Venance, L et al. (2005). Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas. BMC Cell Biol 6: 7.
45. Zhang, W, DeMattia, JA, Song, H and Couldwell, WT (2003). Communication between malignant glioma cells and vascular endothelial cells through gap junctions. J Neurosurg 98: 846-853.
46. Fechner, H, Wang, X, Pico, AH, Wildner, J, Suckau, L, Pinkert, S et al. (2007). A bidirectional Tet-dependent promotor construct regulating the expression of E1A for tight control of oncolytic adenovirus replication. J Biotechnol 127: 560-574.
47. Jimenez, T, Fox, WP, Naus, CC, Galipeau, J and Belliveau, DJ (2006). Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy. Cell Commun Adhes 13: 79-92.
48. Martuza, RL and Eldridge, R (1988). Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med 318: 684-688.
49. Sena-Esteves, M, Saeki, Y, Camp, SM, Chiocca, EA and Breakefield, XO (1999). Single-step conversion of cells to retrovirus vector producers with herpes simplex virus-Epstein-Barr virus hybrid amplicons. J Virol 73: 10426-10439.
50. García-Añoveros, J, Samad, TA, Zuvela-Jelaska, L, Woolf, CJ and Corey, DP (2001). Transport and localization of the DEG/ENaC ion channel BNaC1alpha to peripheral mechanosensory terminals of dorsal root ganglia neurons. J Neurosci 21: 2678-2686.